Freezing Cellular Raw Materials For Cell Therapy Production
Cellular raw materials support the future of medicine
When Dr. Edward Scott started his career as a hematologist in the 1970s, he diagnosed blood cancers, such as leukemia and lymphoma, and treated them with traditional methods such as chemotherapy, transfusions, and bone marrow transplants.
But as medical technologies evolved, he found himself leading a company that isolated and captured components of the blood called mononuclear (MNC) cells. MNCs, such as lymphocytes, monocytes, and dendritic cells, are critical to the immune system – and an integral component in today’s cutting-edge cell therapies.
Now president of Key Biologics, Dr. Scott supports customers with the cellular raw materials needed to develop the latest medical discoveries. Since 1999, the Memphis, Tennessee-based business has provided research and clinical-grade human cells and blood products to pharmaceutical, biotech, medical device, and academic institutions around the world.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.